Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.

175.20 8.97 −4.87%
Market cap
$11.7B
P/E
234×
Fwd P/E
112×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
738.26 634.44 632.36 801.54 670.53 366.26 270.25 194.03 141.24 104.54
Revenue Growth
16.36% 0.33% (21.11%) 19.54% 83.08% 35.53% 39.28% 37.38% 35.10% 25.14%
Cost of Revenue
352.01 359.79 353.92 345.83 279.28 156.63 119.10 86.53 67.05 47.12
Gross Profit
386.25 274.65 278.44 455.71 391.25 209.63 151.15 107.50 74.19 57.42
R&D Expenses
54.18 43.20 42.72 43.94 34.27 20.18 19.45 15.82 8.67 7.36
SG&A Expenses
290.51 263.37 218.58 215.83 183.87 119.62 95.61 65.69 51.51 30.85
Operating Income
55.17 (35.11) 47.70 224.67 167.25 69.82 36.08 25.99 14.01 15.97
Non-operating Income/Expense
7.22 8.08 9.00 (5.53) (13.71) (10.61) (9.93) (4.55) (6.76) (4.28)
Non-operating Interest Expenses
21.51 20.73 2.50 1.16 11.28 10.77 9.29 6.71 6.44 3.77
EBT
62.38 (27.03) 56.71 219.14 153.54 59.22 26.15 21.44 7.25 11.69
Income Tax Provision
13.49 (1.52) 21.11 33.18 25.25 (0.71) 4.74 4.82 (21.10) 0.01
Income after Tax
48.89 (25.51) 35.60 185.96 128.29 59.93 21.41 16.62 28.35 11.68
Dividends (Preferred)
0.00 — 0.00 — — — — — — 0.00
Net Income Common
48.89 (25.51) 35.60 185.96 128.29 59.93 21.41 16.62 28.35 11.68
EPS (Basic)
0.87 (0.46) 0.75 3.35 2.33 1.14 0.44 0.38 0.74 0.35
EPS (Diluted)
0.86 (0.46) 0.74 3.24 2.24 1.11 0.44 0.37 0.72 0.34
Shares (Basic, Weighted)
56.23 55.94 55.72 55.46 55.02 52.55 48.34 43.77 38.23 33.57
Shares (Diluted, Weighted)
56.56 55.94 56.38 57.46 57.26 53.89 49.21 45.47 39.15 34.10
Gross Margin
52.32% 43.29% 44.03% 56.85% 58.35% 57.23% 55.93% 55.40% 52.53% 54.93%
EBIT Margin
7.47% (5.53%) 7.54% 28.03% 24.94% 19.06% 13.35% 13.39% 9.92% 15.28%
EBT margin
8.45% (4.26%) 8.97% 27.34% 22.90% 16.17% 9.68% 11.05% 5.13% 11.18%
Net Profit Margin
6.62% (4.02%) 5.63% 23.20% 19.13% 16.36% 7.92% 8.56% 20.07% 11.17%
Free Cash Flow Margin
12.45% 22.46% 11.85% 4.83% 7.12% 9.91% 16.30% 9.65% 8.49% 3.10%
EBITDA
150.56 50.15 118.71 277.47 217.23 107.86 64.49 46.01 24.51 21.31
EBIT
55.17 (35.11) 47.70 224.67 167.25 69.82 36.08 25.99 14.01 15.97
Income from Continuous Operations
48.89 (25.51) 35.60 185.96 128.29 59.93 21.41 16.62 28.35 11.68
Consolidated Net Income/Loss
48.89 (25.51) 35.60 185.96 128.29 59.93 21.41 16.62 28.35 11.68
EPS (Basic, from Continuous Ops)
0.87 (0.46) 0.64 3.35 2.33 1.14 0.44 0.38 0.74 0.35
EPS (Basic, Consolidated)
0.87 (0.46) 0.64 3.35 2.33 1.14 0.44 0.38 0.74 0.35
EPS (Diluted, from Cont. Ops)
0.86 (0.46) 0.63 3.24 2.24 1.11 0.44 0.37 0.72 0.34
Shares (Diluted, Average)
56.56 55.94 56.38 57.46 57.26 53.89 49.21 45.47 39.15 34.10
EPS (Diluted, Consolidated)
0.86 (0.46) 0.63 3.24 2.24 1.11 0.44 0.37 0.72 0.34
EBITDA Margin
20.39% 7.90% 18.77% 34.62% 32.40% 29.45% 23.86% 23.71% 17.36% 20.38%
Operating Cash Flow Margin
15.90% 27.65% 18.01% 21.47% 17.75% 17.10% 24.87% 16.89% 12.36% 7.19%

Fold the line items

In millions of $ except per-share values · columns are period end dates